Form 8-K PTC THERAPEUTICS, INC. For: Sep 15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St futures gain on tech rebound, Middle East peace hopes
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil gains after Trump says US will hit Iran 'very hard tonight'
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
PTC Therapeutics (PTCT) PT Lowered to $45 at Truist Securities; 'PTC isn't dead'
September 18, 2023 6:14 AM EDTTruist Securities analyst Robyn Karnauskas lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $45.00 (from $60.00) while maintaining a Buy rating.
THE analyst commented, "In addition to the negative CHMP decision, we believe concerns about cash position and mgmt's ability to... More
PTC Therapeutics (PTCT) PT Lowered to $53 at JPMorgan, 'Late Stage Assets Remain Significantly Underappreciated'
September 15, 2023 12:50 PM EDTJPMorgan analyst Eric Joseph lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $53.00 (from $70.00) while maintaining a Overweight rating.
The analyst comments "Were lowering our Dec -24 PT ($53/sh vs $70 prior) but maintaining our Overweight rating following the negative CHMP opinion regarding full / extended conditional marketing authorization... More
